Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability of PF-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.

Next Previous
Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability of PF-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 13 Oct 2017 Results (n=189) assessing the effect of bococizumab on LDL, VLDL, and HDL particle concentration and size in hypercholesterolemic subjects using patient data pooled from NCT01243151, NCT01342211, and NCT01350141 trials published in the Clinical Therapeutics
  • 30 Jul 2012 Actual initiation date changed from 1 Jul 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
  • 30 Jul 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top